| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/19/2011 | EP2275414A1 Cyclopentylacrylic acid amide derivative |
| 01/19/2011 | EP2275413A1 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders. |
| 01/19/2011 | EP2275411A2 Reformatsky Reagent in Stable Form and Process for Producing the Same |
| 01/19/2011 | EP2275410A1 Process for production of compound having antagonistic activity on npyy5 receptor, and useful crystal |
| 01/19/2011 | EP2275404A1 Homocysteine synthase inhibitor |
| 01/19/2011 | EP2275401A1 Crystalline 1-{[(a-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid |
| 01/19/2011 | EP2275154A1 Antibacterial composition for medical use and medical device |
| 01/19/2011 | EP2275143A2 Conjugated anti-psychotic drugs and uses thereof |
| 01/19/2011 | EP2275141A1 Tastemasked pharmaceutical compositions |
| 01/19/2011 | EP2275140A2 Composition comprising plant and/or fish oils and non-oxidizable fatty acid entities |
| 01/19/2011 | EP2275139A1 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID |
| 01/19/2011 | EP2275138A1 Promoter for bicarbonate secretion in gastrointestinal tract |
| 01/19/2011 | EP2275135A1 Therapeutic for hepatic cancer |
| 01/19/2011 | EP2275113A1 Skin circulation-improving agent and skin temperature-elevating agent |
| 01/19/2011 | EP2275112A1 Antitumoral terpenoid pharmaceutical composition 'abisilin' exhibiting angiogenesis-inhibiting action |
| 01/19/2011 | EP2275111A1 Enteral nutrient |
| 01/19/2011 | EP2275110A2 Cladribine regimen for treating Multiple Sclerosis |
| 01/19/2011 | EP2275109A2 Pregnane steroids for use in the treatment of CNS disorders |
| 01/19/2011 | EP2275108A1 Pharmaceutical preparation comprising dpp-iv inhibitor and other diabetes therapeutic agent in concomitant or combined form |
| 01/19/2011 | EP2275107A2 Combinations for the treatment of diseases involving cell proliferation |
| 01/19/2011 | EP2275106A1 Combination drug containing probucol and a tetrazolylalkoxy-dihydrocarbostyril derivative with superoxide supressant effects |
| 01/19/2011 | EP2275105A1 Heterocyclic derivatives as opioid receptor modulators |
| 01/19/2011 | EP2275104A2 Pharmaceutical and cosmetic composition including lactoferrin, ciclopirox and etidronic acid |
| 01/19/2011 | EP2275103A2 mTOR inhibitors in the treatment of endocrine tumors |
| 01/19/2011 | EP2275102A1 N3 alkylated benzimidazole derivatives as MEK inhibitors |
| 01/19/2011 | EP2275101A1 Polar lipid-rich fraction containing stearidonic acid and gamma linolenic acid from plant seeds and microbes, and its uses |
| 01/19/2011 | EP2275100A2 Compounds with anti-parasitic activity and drugs containing said compounds |
| 01/19/2011 | EP2275099A1 Treatment of faecal incontinence with 1r,2s-methoxamine |
| 01/19/2011 | EP2275098A1 Novel oral formulations of ospemifene |
| 01/19/2011 | EP2275097A1 Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions |
| 01/19/2011 | EP2275096A2 Neurogenesis via modulation of the muscarinic receptors |
| 01/19/2011 | EP2275095A2 Neurogenesis by muscarinic receptor modulation |
| 01/19/2011 | EP2275093A2 Pharmaceutical formulation |
| 01/19/2011 | EP2275092A1 Taxane pharmaceutical formulation |
| 01/19/2011 | EP2275091A1 Pharmaceutical compositions comprising adsorbates of an amorphous drug |
| 01/19/2011 | EP2275089A1 Preparation of biodegradable microparticles containing a biologically active agent |
| 01/19/2011 | EP2275088A2 Method for producing granules |
| 01/19/2011 | EP2275087A1 Prasugrel controlled release formulations |
| 01/19/2011 | EP2275083A1 Extract produced from orchid family plant, method for production thereof, and preparation for external application to skin comprising extract produced from orchid family plant |
| 01/19/2011 | EP2275075A2 Method of measuring an iron-saccharidic complex |
| 01/19/2011 | EP2274427A2 Tat dna sequences, gene constructs, vaccine and processes thereof |
| 01/19/2011 | EP2274424A2 Reprogramming a cell by inducing a pluripotent gene through use of an hdac modulator |
| 01/19/2011 | EP2274423A2 Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity |
| 01/19/2011 | EP2274317A1 Synthesis of timosaponin bii |
| 01/19/2011 | EP2274316A1 Ligands of estrogen receptors and , method of their preparation and pharmaceuticals comprising them |
| 01/19/2011 | EP2274315A1 Compositions comprising galactomannan and a process thereof |
| 01/19/2011 | EP2274311A2 Compounds and methods for the treatment of viral infection |
| 01/19/2011 | EP2274309A1 Halichondrin b analogs |
| 01/19/2011 | EP2274308A1 Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors |
| 01/19/2011 | EP2274307A1 Bridged heterocyclic compounds and methods of use |
| 01/19/2011 | EP2274306A1 Novel compounds as cannabinoid receptor ligands |
| 01/19/2011 | EP2274304A1 Method of treating cancer using a cmet and axl inhibitor and an erbb inhibitor |
| 01/19/2011 | EP2274303A1 Processes for preparing sunitinib and salts thereof |
| 01/19/2011 | EP2274302A2 Compounds and compositions as itpkb inhibitors |
| 01/19/2011 | EP2274301A1 Aza-bicyclohexyl substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
| 01/19/2011 | EP2274299A1 Heteroaryl-substituted dicyanopyridines and use thereof for treatment of cardiovascular diseases |
| 01/19/2011 | EP2274297A1 Pyrrolidinone glucokinase activators |
| 01/19/2011 | EP2274296A1 Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists |
| 01/19/2011 | EP2274295A1 3, 4 - substituted piperidine derivatives as renin inhibitors |
| 01/19/2011 | EP2274294A1 5-demethoxyfumagillol and derivatives thereof |
| 01/19/2011 | EP2274293A1 Methods for synthesizing kotalanol and stereoisomers and analogues thereof, and novel compounds produced thereby |
| 01/19/2011 | EP2274290A2 Linear and cyclic guanidine derivatives, method of preparation and uses thereof |
| 01/19/2011 | EP2274287A1 Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
| 01/19/2011 | EP2274285A1 Novel pyrazole derivatives |
| 01/19/2011 | EP2274283A1 Novel n-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds |
| 01/19/2011 | EP2274282A1 Compounds for use in stabilizing p53 mutants |
| 01/19/2011 | EP2274281A1 Hcv protease inhibitors |
| 01/19/2011 | EP2274280A2 Bis-aryl compounds for use as medicaments |
| 01/19/2011 | EP2274279A1 Nitric oxide donating prostamides |
| 01/19/2011 | EP2274007A2 Modulation of blood brain barrier permeability |
| 01/19/2011 | EP2274003A1 Composition and method for the inhibition of postoperative adhesions severity |
| 01/19/2011 | EP2273995A2 Destruction of microbial products by enzymatic digestion |
| 01/19/2011 | EP2273994A2 Solid state forms of a pharmaceutical |
| 01/19/2011 | EP2273993A1 Methods and compositions for the intracerebroventricular administration of felbamate |
| 01/19/2011 | EP2273992A1 Quenolines and related analogs as sirtuin modulators |
| 01/19/2011 | EP2273991A1 3-hydroxy gepirone for the treatment of attention deficit disorder and sexual dysfunction |
| 01/19/2011 | EP2273990A2 Solid state forms of aliskiren compounds |
| 01/19/2011 | EP2273989A1 Combination therapy for the treatment of bacterial infections |
| 01/19/2011 | EP2273988A2 Methods and compositions for treating and identifying compounds to treat age-related macular degeneration |
| 01/19/2011 | EP2273985A2 Capsule for the prevention of cardiovascular diseases |
| 01/19/2011 | EP2273984A2 Lipid composition |
| 01/19/2011 | EP2273982A2 Drug depots having different release profiles for reducing, preventing or treating pain and inflammation |
| 01/19/2011 | EP2273981A2 A solid pharmaceutical formulation |
| 01/19/2011 | EP2273980A2 Pharmaceutical composition with bisphosphonate |
| 01/19/2011 | EP2273975A1 Pharmaceutical solutions, process of preparation and therapeutic uses |
| 01/19/2011 | EP2273974A2 Proguanil to treat skin/mucosal diseases |
| 01/19/2011 | EP2273969A1 Topical composition for external use and process for producing the same |
| 01/19/2011 | EP2273895A1 Compositions comprising myristic acid, fatty acids comprising a conjugated diene n 5cis, n 7trans or a conjugated triene n 5cis, n 7trans, n 9cis |
| 01/19/2011 | EP2273882A1 Bioactive compounds for treatment of cancer and neurodegenerative diseases |
| 01/19/2011 | EP2273881A1 Compounds and methods for altering bone growth |
| 01/19/2011 | EP2273880A1 Novel formulations for treatment of migraine |
| 01/19/2011 | EP2273879A1 Prolyl hydroxylase inhibitors |
| 01/19/2011 | EP2273877A1 Cyclobutyl sulfones as notch sparing gamma secretase inhibitors |
| 01/19/2011 | EP2273876A2 Stabilized compositions of alkylating agents and methods of using same |
| 01/19/2011 | EP2246327A9 A process for isolation of lutein and zeaxanthin crystals from plant sources |
| 01/19/2011 | EP2231131B1 Formulations of organo-platinic compounds in the presence of associative polymers, products thus obtained and uses thereof |
| 01/19/2011 | EP2155229B1 Composition for transmucosal delivery of polypeptides |
| 01/19/2011 | EP2150546B1 Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase |
| 01/19/2011 | EP2150527B1 Anthranilic acid derivative as anticancer agent and a process for the preparation thereof |
| 01/19/2011 | EP2142193B1 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of pain or residual symptoms in depression relating to sleep and cognition |